Dyslipidemia, which occurs in 45 - 60% of cases following LT, is related to the use of calcineurin inhibitors and mammalian target of rapamycin mTOR.
La dislipidemia se presenta en 45 a 60% después del TH. Se relaciona al uso de ICN y mTor.